{"id":6215,"date":"2021-09-07T13:45:00","date_gmt":"2021-09-07T13:45:00","guid":{"rendered":"https:\/\/realheart.se\/mfn_news\/realhearts-ceo-speaking-at-the-esao-congress-on-september-10\/"},"modified":"2021-09-07T13:45:00","modified_gmt":"2021-09-07T13:45:00","slug":"realhearts-ceo-speaking-at-the-esao-congress-on-september-10","status":"publish","type":"mfn_news","link":"https:\/\/realheart.se\/sv\/mfn_news\/realhearts-ceo-speaking-at-the-esao-congress-on-september-10\/","title":{"rendered":"Realheart\u2019s CEO speaking at the ESAO Congress on September 10"},"content":{"rendered":"
On 10 September, Realheart's CEO Ina Laura Perkins will appear at the European Society for Artificial Organs' annual congress. She will give two separate lectures, one on blood research and one on Realheart's process of developing the world's first artificial four-chamber heart.<\/strong><\/div>\n

ESAO 2021 will take place digitally from London on September 7-11. Participants will have the opportunity to present their latest research findings and engage in discussions with clinicians, scientists and engineers from both the public and private sectors on the development of lasting artificial organs. <\/span><\/span><\/p>\n

Ina Laura Perkins will give two lectures, both on Friday September 10: <\/span><\/span><\/p>\n

The first is during the session Blood Damage II \u2013 Recent Progress with Haemolysis<\/strong> at 11:00-12:30, where she will discuss factors affecting the outcome of haemolysis tests. Ina Laura Perkins started her academic career in stem cell research and has devoted her entire career to medical innovations related to the blood. Her vast knowledge in this field is why she was invited to speak on this topic.\u00a0 <\/span><\/span><\/p>\n

Her presentation during the Latest Developments of TAH and RVAD<\/strong> session at 16:00-17:30 will focus specifically on Realheart. Here she will share lessons learned from the previous Realheart prototype and talk about the next steps in the development of the final product. <\/span><\/span><\/p>\n

The full programme is available here: http:\/\/esao2021.org\/wp-content\/uploads\/2021\/09\/Final-Programme-and-Book-of-Abstracts-Final-06.09.21.pdf.<\/span><\/span><\/p>\n

\n

For more information please contact:<\/span><\/span><\/strong><\/span><\/p>\n

Ina Laura Perkins, CEO<\/span><\/span><\/p>\n

Phone: +46(0)70 406 49 21\u00a0<\/span><\/span><\/p>\n

E-mail: inalaura.pieper@realheart.se<\/span><\/span><\/p>\n<\/div>\n

\n

Scandinavian Real Heart AB develops a total artificial heart (TAH) for implantation in patients with life-threatening heart failure. Realheart TAH has a unique, patented design that resembles that of the natural human heart. The artificial heart consists of a four-chamber system (two atriums and two chambers) which provides the opportunity to generate a physiologically adapted blood flow that mimics the body's natural circulation. A unique concept in the medical technology world.<\/span><\/em><\/span><\/span><\/span><\/p>\n<\/div>\n